News Archives: February, 2020

A randomized, controlled clinical trial to evaluate the safety and efficacy of the investigational antiviral remdesivir in hospitalized adults diagnosed with coronavirus disease 2019 (COVID-19) has begun at the University of Nebraska Medical Center (UNMC) in Omaha. The regulatory sponsor of the trial is the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health. This is the first clinical trial in the United States to evaluate an experimental treatment for COVID-19, the respiratory disease first detected in December 2019 in Wuhan, Hubei Province, China.

Deadline: May 12, 2020; April 13, 2021; Second Tuesday in April, Annually Thereafter.

The NSF 2026 Idea Machine encouraged individuals from all walks of life, age 14 or older, to submit pressing “grand challenges” requiring fundamental research in science, engineering, or STEM education in order to inform NSF’s long-term planning. Approximately 800 entries were received from nearly every state in the U.S. and from established researchers, undergraduate and graduate students, teachers on behalf of their classes, and high school and middle school students. The submitted entries went through five selection stages, including a public comment phase. A blue-ribbon panel of 12 eminent, broad thinkers recommended seven ideas for the final prizes that were found to be exciting, ambitious, creative, and highly interdisciplinary.